- Home
- GNRC vs BIO Comparison
GNRC vs BIO Comparison
Compare GNRC & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNRC
- BIO
- Stock Information
- Founded
- GNRC 1959
- BIO 1952
- Country
- GNRC United States
- BIO United States
- Employees
- GNRC N/A
- BIO N/A
- Industry
- GNRC Metal Fabrications
- BIO Biotechnology: Laboratory Analytical Instruments
- Sector
- GNRC Consumer Discretionary
- BIO Industrials
- Exchange
- GNRC Nasdaq
- BIO Nasdaq
- Market Cap
- GNRC 10.9B
- BIO 9.1B
- IPO Year
- GNRC 2010
- BIO N/A
- Fundamental
- Price
- GNRC $160.54
- BIO $342.01
- Analyst Decision
- GNRC Buy
- BIO Strong Buy
- Analyst Count
- GNRC 20
- BIO 4
- Target Price
- GNRC $177.78
- BIO $414.00
- AVG Volume (30 Days)
- GNRC 665.9K
- BIO 158.1K
- Earning Date
- GNRC 02-12-2025
- BIO 02-13-2025
- Dividend Yield
- GNRC N/A
- BIO N/A
- EPS Growth
- GNRC 89.80
- BIO N/A
- EPS
- GNRC 4.82
- BIO N/A
- Revenue
- GNRC $4,124,703,000.00
- BIO $2,580,209,000.00
- Revenue This Year
- GNRC $9.21
- BIO N/A
- Revenue Next Year
- GNRC $8.29
- BIO $2.92
- P/E Ratio
- GNRC $33.32
- BIO N/A
- Revenue Growth
- GNRC 2.91
- BIO N/A
- 52 Week Low
- GNRC $108.89
- BIO $262.12
- 52 Week High
- GNRC $195.94
- BIO $387.99
- Technical
- Relative Strength Index (RSI)
- GNRC 44.08
- BIO 53.78
- Support Level
- GNRC $153.25
- BIO $335.42
- Resistance Level
- GNRC $162.17
- BIO $351.96
- Average True Range (ATR)
- GNRC 3.93
- BIO 9.09
- MACD
- GNRC 1.06
- BIO 2.06
- Stochastic Oscillator
- GNRC 76.61
- BIO 59.23
About GNRC Generac Holdlings Inc.
Generac designs and manufactures power generation equipment serving residential, commercial, and industrial markets. It offers standby generators, portable generators, lighting, outdoor power equipment, and a suite of clean energy products. Sales generated in the United States account for the majority of total sales.
About BIO Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.